M. Cyrus Maher

M. Cyrus Maher

Auto-generated profile, based on publicly available information

M. Cyrus Maher

Vir Biotechnology, San Francisco, California 94158, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Nature
Verified
Journal Article
Closed access
ECElisabetta Cameroni
Elisabetta Cameroni
JBJohn E. Bowen
John E. Bowen
LRLaura E. Rosen
Laura E. Rosen
CSChristian Saliba
Christian Saliba
SZSamantha K. Zepeda
Samantha K. Zepeda
DCDavide Corti
Davide Corti

23 February 2022 in Science Translational Medicine
Verified
Journal Article
Open access
MMM. Cyrus Maher
M. Cyrus Maher
IBIstvan Bartha
Istvan Bartha
SWSteven Weaver
Steven Weaver
JIJulia di Iulio
Julia di Iulio
EFElena Ferri
Elena Ferri
Amalio TelentiAmalio Telenti
Amalio Telenti
SARS-CoV-2 evolution threatens vaccine- and natural infection–derived immunity and the efficacy of therapeutic antibodies. To improve public health preparedness, we sought to predict which existing amino acid mutations in SARS-CoV-2 might contribute to future variants of concern. We tested the predictive value of features comprising epidemiology, evolution, immunology, and neural network–based protein sequence modeling and identified primary biological drivers of SARS-CoV-2 intrapandemic evolution. We found evidence that ACE2-mediated transmissibility and resistance to population-level host immunity has waxed and waned as a primary driver of SARS-CoV-2 evolution over time. We retroactively identified with high accuracy (area under the receiver operator characteristic curve = 0.92 to 0.97) mutations that will spread, at up to 4 months in advance, across different phases of the pandemic. The behavior of the model was consistent with a plausible causal structure where epidemiological covariates combine the effects of diverse and shifting drivers of viral fitness. We applied our model to forecast mutations that will spread in the future and characterize how these mutations affect the binding of therapeutic antibodies. These findings demonstrate that it is possible to forecast the driver mutations that could appear in emerging SARS-CoV-2 variants of concern. We validated this result against Omicron, showing elevated predictive scores for its component mutations before emergence and rapid score increase across daily forecasts during emergence. This modeling approach may be applied to any rapidly evolving pathogens with sufficiently dense genomic surveillance data, such as influenza, and unknown future pandemic viruses.

22 June 2021 in medRxiv
Verified
Preprint
Open access
PDF file
MMM. Cyrus Maher
M. Cyrus Maher
IBIstvan Bartha
Istvan Bartha
SWSteven Weaver
Steven Weaver
JIJulia di Iulio
Julia di Iulio
EFElena Ferri
Elena Ferri
Amalio TelentiAmalio Telenti
Amalio Telenti
SARS-CoV-2 evolution threatens vaccine- and natural infection-derived immunity, and the efficacy of therapeutic antibodies. Herein we sought to predict Spike amino acid changes that could contribute to future variants of concern. We tested the importance of features comprising epidemiology, evolution, immunology, and neural network-based protein sequence modeling. This resulted in identification of the primary biological drivers of SARS-CoV-2 intra-pandemic evolution. We found evidence that resistance to population-level host immunity has increasingly shaped SARS-CoV-2 evolution over time. We identified with high accuracy mutations that will spread, at up to four months in advance, across different phases of the pandemic. Behavior of the model was consistent with a plausible causal structure wherein epidemiological variables integrate the effects of diverse and shifting drivers of viral fitness. We applied our model to forecast mutations that will spread in the future, and characterize how these mutations affect the binding of therapeutic antibodies. These findings demonstrate that it is possible to forecast the driver mutations that could appear in emerging SARS-CoV-2 variants of concern. This modeling approach may be applied to any pathogen with genomic surveillance data, and so may address other rapidly evolving pathogens such as influenza, and unknown future pandemic viruses.

28 October 2021 in Journal of Computational Chemistry
Verified
Journal Article
Closed access
PDF file
EAEric Alcaide
Eric Alcaide
SBStella Biderman
Stella Biderman
ATAmalio Telenti
Amalio Telenti
MMM. Cyrus Maher
M. Cyrus Maher

16 August 2022 in Cell Reports Medicine
Verified
Journal Article
Open access
MMM. Cyrus Maher
M. Cyrus Maher
LSLeah B. Soriaga
Leah B. Soriaga
AGAnil Gupta
Anil Gupta
YCYi-Pei Chen
Yi-Pei Chen
JIJulia di Iulio
Julia di Iulio
Amalio TelentiAmalio Telenti
Amalio Telenti
Understanding who is at risk of progression to severe coronavirus disease 2019 (COVID-19) is key to clinical decision making and effective treatment. We study correlates of disease severity in the COMET-ICE clinical trial that randomized 1:1 to placebo or to sotrovimab, a monoclonal antibody for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (ClinicalTrials.gov 04545060). Laboratory parameters identify study participants at greater risk of severe disease, including a high neutrophil-to-lymphocyte ratio (NLR), a negative SARS-CoV-2 serologic test, and whole-blood transcriptome profiles. Sotrovimab treatment is associated with normalization of NLR and the transcriptomic profile and with a decrease of viral RNA in nasopharyngeal samples. Transcriptomics provides the most sensitive detection of participants who would go on to be hospitalized or die. To facilitate timely measurement, we identify a 10-gene signature with similar predictive accuracy. We identify markers of risk for disease progression and demonstrate that normalization of these parameters occurs with antibody treatment of established infection.

9 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
EAEric Alcaide
Eric Alcaide
SBStella Biderman
Stella Biderman
Amalio TelentiAmalio Telenti
Amalio Telenti
MMM. Cyrus Maher
M. Cyrus Maher
The conversion of proteins between internal and cartesian coordinates is a limiting step in many pipelines, such as molecular dynamics simulations and machine learning models. This conversion is typically carried out by sequential or parallel applications of the Natural extension of Reference Frame (NeRF) algorithm. This work proposes a massively parallel NeRF implementation which, depending on the polymer length, achieves speedups between 400-1200x over the previous state-of-the-art. It accomplishes this by dividing the conversion into three main phases: parallel composition of the monomer backbone, assembly of backbone subunits, and parallel elongation of sidechains; and by batching these computations into a minimal number of efficient matrix operations. Special emphasis is placed on reusability and ease of use. We open source the code (available at https://github.com/EleutherAI/mp_nerf ) and provide a corresponding python package.